JAMA Oncology : Anti–PD-L1 Plus Targeted Therapy in Anaplastic Thyroid Carcinoma

JAMA Network - A podcast by The JAMA Network

Categories:

Science & Medicine

Interview with Maria E. Cabanillas, MD, author of Anti–Programmed Death Ligand 1 Plus Targeted Therapy in Anaplastic Thyroid Carcinoma: A Nonrandomized Clinical Trial. Hosted by Vivek Subbiah, MD. Related Content: Anti–Programmed Death Ligand 1 Plus Targeted Therapy in Anaplastic Thyroid Carcinoma